Rasburicase
Tumor Lysis Syndrome
M.D. Anderson Cancer Centerprotein_peptidePhase 4 / ApprovedActive
A
80/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 70/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Tumor Lysis Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pegloticase M.D. Anderson Cancer Center | Phase 4 | BB |
Allopurinol Menarini Group | Phase 3 | BB |
Febuxostat Menarini Group | Phase 3 | BB |
Same molecule, other indications
Rasburicase is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →